Search

Author/Creator Sperbeck, Donald

1. Ibrexafungerp: An orally active β-1, 3-glucan synthesis inhibitor. (15th January 2021)

Authors:
Apgar, James M.; Wilkening, Robert R.; Parker, Dann L.; Meng, Dongfang; Wildonger, Kenneth J.; Sperbeck, Donald; Greenlee, Mark L.; Balkovec, James M.; Flattery, Amy M.; Abruzzo, George K.; Galgoci, Andrew M.; Giacobbe, Robert A.; Gill, Charles J.; Hsu, Ming-Jo; Liberator, Paul; Misura, Andrew S....
Journal:
Bioorganic & medicinal chemistry letters
Issue:
Volume 32(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. MK-5204: An orally active β-1, 3-glucan synthesis inhibitor. Issue 17 (1st September 2020)

Authors:
Apgar, James M.; Wilkening, Robert R.; Parker, Dann L.; Meng, Dongfang; Wildonger, Kenneth J.; Sperbeck, Donald; Greenlee, Mark L.; Balkovec, James M.; Flattery, Amy M.; Abruzzo, George K.; Galgoci, Andrew M.; Giacobbe, Robert A.; Gill, Charles J.; Hsu, Ming-Jo; Liberator, Paul; Misura, Andrew S....
Journal:
Bioorganic & medicinal chemistry letters
Issue:
Volume 30:Issue 17(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search